Bionano Genomics (Bionano Genomics) Short Percentage of Float

View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Bionano Genomics's Short Percentage of Float

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Short Percentage of Float falls into.

Bionano Genomics (Bionano Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGOW) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

BNGO:USA BNGO:Mexico

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.